RetinAI will attend AAO 2022 & is excited to introduce advances in AI for GA analysis & Progression Prediction & Discovery CORE™

Latest press releases

RetinAI Expands Operations to Set Up a U.S. Office In Boston and Achieves 21 CFR Part 11 Compliance to Support Research and Clinical Studies

RetinAI, a leader in clinical and imaging data management software and advanced analytics for ophthalmology, is excited to announce the launch of its first U.S.-based office, located in Boston, MA. This expansion will support further growth within the U.S. market, building upon existing collaborations with U.S.-based pharmaceutical companies and its partnership with Heidelberg Engineering to distribute RetinAI’s Disease AI Apps for research use in the U.S. The Boston office will be RetinAI’s second location, in addition to its Bern headquarters.

RetinAI will attend EURETINA 2022 from September 1st to 4th in Hamburg

RetinAI will attend the 22nd EURETINA Congress, from September 1st to 4th, at the CCH (Congress Centre Hamburg) in Hamburg, Germany. EURETINA 2022 attendees will get first-hand insights on the company’s two new products: Our new data management platform, Discovery CORE, designed to share data in a privacy-preserving and secure manner across a network of collaborators, fostering and facilitating knowledge network building, vendor-neutral collaborative data analysis & management, education, training and teleophthalmology. Our Disease Evaluation Apps on Heidelberg Engineering’s secure data workflow solution, called AppWay, for connecting to AI applications.

RetinAI attends OIS Retina Innovation Summit and ASRS 2022 Annual Meeting from July 13th to 16th in New York

RetinAI will attend the OIS Retina Innovation Summit on July 13th at the Edison Ballroom NYC, and the ASRS 2022 Annual Meeting, from July 14th to 16th, at the Javits Convention Center in New York. ASRS attendees who visit RetinAI at Booth #625 will benefit from learning and seeing live demos on RetinAIs latest products and services.

RetinAI announces multi-year software license and services agreement for RetinAI Discovery® UNITY platform

RetinAI announces a multi-year license and services agreement with Novartis AG (“Novartis”) for its Discovery® UNITY platform. Discovery UNITY is RetinAI’s top of the line enterprise-wide solution to aggregate imaging data for global organizations, including data from clinical and real-world evidence studies, with AI that can be applied to improve understanding of patient populations and outcomes at scale.

Latest updates

Fully-automated atrophy segmentation in dry age-related macular degeneration in optical coherence tomography - Scientific Reports

RetinAI is thrilled to introduce our novel method for the segmentation of atrophy with performance matching human experts published in Scientific Reports and developed in collaboration with the Fondation Asile des aveugles, Hôpital ophtalmique Jules-Gonin in Lausanne. Congratulations to both teams for this success!

Full Article -

Authors: Yasmine Derradji, Agata Mosinska, Stefanos Apostolopoulos, Carlos Ciller, Sandro De Zanet & Irmela Mantel Widmer

Automatic Atrophy Progression Prediction in Age-Related Macular Degeneration in EURETINA 2021

We are happy to present our novel method for prediction of continuous atrophy growth for follow-up periods of 4 years and longer in this year's EURETINA 2021. Congratulations to our collaborators and team members for this great poster.

We enable for the first time the creation of atrophy risk maps, which present the risk of retinal regions being affected by the atrophy in the future.

Authors: Agata Mosinska, Anthony Gigon, Stefanos Apostolopoulos, Carlos Ciller, Irmela Mantel Widmer, Sandro De Zanet

RetinAI in Top 100 Swiss Startups for 2021

RetinAI is proud to be recognized as one of the TOP 100 Swiss Startups for 2021. Check out the ‘Hall of Fame’ on to see Retinai again in the list this year.

Huge thanks to everyone in the team, to our supporters, and to our partners for believing in us along the way and for supporting us to define the future of Digital Precision Medicine!

First Peer-reviewed Publication around the RAZORBILL Study

The very first peer-reviewed publication around the RAZORBILL study has been published in the British journal of Ophthalmology (BJO).

'Does real-time artificial intelligence-based visual pathology enhancement of three-dimensional optical coherence tomography scans optimise treatment decision in patients with nAMD? Rationale and design of the RAZORBILL study'

A first of its class international multi-center clinical study to assess the influence of automated 3D OCT scan enrichment with segmentation information on disease activity assessment in patients with nAMD treated with either brolucizumab, ranibizumab or aflibercept.

We are glad to be supporting this initiative together with a leading team of world renown ophthalmologists & Novartis!

Contact us for more informations! We are happy to hear from you!